Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (DE:EXK)
FRANKFURT:EXK
Exact Sciences (EXK) Stock Price & Analysis
1 Followers
EXK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€51.27 - €94.79
Previous Close€55.8
Volume110.00
Average Volume (3M)95.00
Market Cap
€10.30B
Enterprise Value€12.02B
Total Cash (Recent Filing)$777.64M
Total Debt (Recent Filing)$2.55B
Price to Earnings (P/E)N/A
Beta0.89
Next Earnings
May 08, 2024EPS Estimate
-€0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding181,530,967
10 Day Avg. Volume0
30 Day Avg. Volume95
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-9.79
Price to Sales (P/S)15.32
Price to Cash Flow (P/CF)39.20
P/FCF Ratio64.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.81
Enterprise Value/Gross Profit6.52
Enterprise Value/Ebitda423.17
Forecast
1Y Price Target
€84.07Price Target Upside50.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Exact Sciences News
PremiumStock Analysis & Ideas
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
PremiumCompany Announcements
Exact Sciences Announces Board Member Retirement
PremiumCompany Announcements
Exact Sciences Appoints Aaron Bloomer as New CFO
Bulls Say, Bears Say
Bulls Say
Market ExpansionNew markets for Cologuard Plus are being contemplated, potentially unlocking a $6 billion upside pending USPSTF guidelines.
Product PerformanceExact Sciences' Cologuard demonstrates significantly higher sensitivity compared to Freenome's blood test, indicating a competitive advantage.
Revenue GrowthManagement noted that rescreens represented a significant portion of Screening revenue in 2023 and expects the rescreen pool to increase, indicating potential for revenue growth.
Bears Say
Clinical Trials And ReimbursementEXAS is likely to hold back on its large scale SOAR trial until there is more clarity on the reimbursement pathway for MCEDs from Congress.
Financial GuidanceThe Q1 guide came in below consensus with the company expecting a lighter performance in the first quarter.
Product PerformanceFreenome's blood test for CRC screening underperforms with only 79% sensitivity and 12.5% advanced adenoma sensitivity.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
7.60% Other Institutional Investors
92.40% Public Companies and
Individual Investors
EXK FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was €51.27 and its highest was €94.79 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Currently, no data Available
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is May 08, 2024 which is in 4 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Feb 21, 2024. The company reported -€0.252 earnings per share for the quarter, beating the consensus estimate of -€0.395 by €0.143.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -€0.44.
How many shares outstanding does Exact Sciences Corp. have?
Currently, no data Available
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -€0.252 in its last earnings report, beating expectations of -€0.395. Following the earnings report the stock price went up 1.837%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Among the largest hedge funds holding Exact Sciences Corp.’s share is ARK Investment Management LLC. It holds Exact Sciences Corp.’s shares valued at 446M.
---
Exact Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€84.07 (50.67% Upside)
€84.07 (50.67% Upside)
Blogger Sentiment
Bullish
DE:EXK Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.04%
12-Months-Change
Fundamentals
Return on Equity
-6.60%
Trailing 12-Months
Asset Growth
3.37%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
---
EXK Company Deck
---
EXK Earnings Call
Q4 2024
0:00 / 0:00
---
EXK Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
---
EXK Stock 12 Months Forecast
Average Price Target
€84.07
▲(50.67% Upside)
Technical Analysis
Best Analysts Covering EXK
1 Year
1 Year Success Rate
15/20 ratings generated profit
1 Year Average Return
+35.50%
initiated a buy rating 5 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +35.50% per trade.
---